Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants.

George Washington University, Washington, Washington, D.C., United States
Diabetes Care (Impact Factor: 8.57). 04/2005; 28(4):830-7.
Source: PubMed

ABSTRACT To assess depression markers (symptoms and antidepressant medicine use) in Diabetes Prevention Program (DPP) participants and to determine whether changes in depression markers during the course of the study were associated with treatment arm, weight change, physical activity level, or participant demographic characteristics.
DPP participants (n = 3,187) in three treatment arms (intensive lifestyle, metformin, and placebo) completed the Beck Depression Inventory (BDI) and reported on use of antidepressant medicines at randomization and subsequently at each annual visit (average duration in study 3.2 years).
On study entry, 10.3% of participants had BDI scores > or =11, which was used as a threshold for mild depression, 5.7% took antidepressant medicines, and 0.9% had both depression markers. During the DPP, the proportion of participants with elevated BDI scores declined (from 10.3% at baseline to 8.4% at year 3), while the proportion taking antidepressant medicines increased (from 5.7% at baseline to 8.7% at year 3), leaving the proportion with either marker unchanged. These time trends were not significantly associated with the DPP treatment arm. Depression markers throughout the study were associated with some participant demographic factors, adjusted for other factors. Men were less likely to have elevated depression scores and less likely to use antidepressant medicine at baseline (9.0% of men and 17.9% of women had at least one marker of depression) and throughout the study (P <0.0001). Those with more education were less likely to have elevated symptom scores (P = 0.0007) but more likely to be taking antidepressant medicine (P = 0.002). Non-Hispanic white participants were less likely than African Americans to have BDI scores > or =11 (P = 0.03), but white participants were more likely to be taking antidepressant medicine than any other racial/ethnic group (P <0.0001).
DPP participation was not associated with changes in levels of depression. Countervailing trends in the proportion of DPP participants with elevated depression symptoms and the proportion taking antidepressant medicine resulted in no significant change in the proportion with either marker. The finding that those taking antidepressant medicine often do not have elevated depression symptoms indicates the value of assessing both markers when estimating overall depression rates.

  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim To prospectively examine whether depressive symptoms increase the risk of diabetes and a diabetic foot ulcer. Methods The Nord-Trøndelag Health Study (HUNT) is a community-based longitudinal study. The Hospital Anxiety and Depression Scale (HADS-D subscale) assessed depressive symptoms. We followed individuals with complete HADS-D data from HUNT2 (1995–97) and assessed whether they reported diabetes with or without a history of diabetic foot ulcer (DFU) in HUNT3 (2006–08) (n = 36,031). Logistic regression was used to investigate the effect of depressive symptoms on subsequent development of diabetes and of DFU. Results Unadjusted odds for reporting diabetes at follow-up was higher among individuals who reported a HADS-D score ≥ 8 at baseline (OR 1.30 95% CI, 1.07 – 1.57) than among those reporting a lower score. After adjusting for age, gender and BMI, this association was no longer significant. The odds of developing a DFU was almost two-fold (OR = 1.95 95% CI, 1.02 – 3.74) for those reporting a HADS-D score of 8–10, and 3-fold (OR = 3.06 95% CI, 1.24 – 7.54) for HADS-D scores ≥ 11, compared to HADS-D scores < 8, after adjusting for age, gender and serum glucose. Conclusions Symptoms of depression at baseline is associated with an increased risk of a diabetic foot ulcer in a dose response manner during this 11-year follow-up.
    Journal of Diabetes and its Complications 09/2014; 29(1). DOI:10.1016/j.jdiacomp.2014.09.006 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. We evaluated the effect of a weight gain prevention intervention (Shape Program) on depression among socioeconomically disadvantaged overweight and obese Black women. Methods. Between 2009 and 2012, we conducted a randomized trial comparing a 12-month electronic health-based weight gain prevention intervention to usual primary care at 5 central North Carolina community health centers. We assessed depression with the Patient Health Questionnaire (PHQ-8). We analyzed change in depression score from baseline to 12- and 18-month follow-up across groups with mixed models. We used generalized estimating equation models to analyze group differences in the proportion above the clinical threshold for depression (PHQ-8 score ≥ 10). Results. At baseline, 20% of participants reported depression. Twelve-month change in depression scores was larger for intervention participants (mean difference = -1.85; 95% confidence interval = -3.08, -0.61; P = .004). There was a significant reduction in the proportion of intervention participants with depression at 12 months with no change in the usual-care group (11% vs 19%; P = .035). All effects persisted after we controlled for weight change and medication use. We saw similar findings at 18 months. Conclusions. The Shape Program, which includes no mention of mood, improved depression among socioeconomically disadvantaged Black women. (Am J Public Health. Published online ahead of print July 17, 2014: e1-e8. doi:10.2105/AJPH.2014.302004).
    American Journal of Public Health 07/2014; 104(9):e1-e8. DOI:10.2105/AJPH.2014.302004 · 4.23 Impact Factor

Full-text (2 Sources)

Available from
May 26, 2014